{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:26:25Z","timestamp":1775521585492,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The cause-and-effect relationship of QTc prolongation in Coronavirus disease 2019 (COVID-19) patients has not been studied well.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>We attempt to better understand the relationship of QTc prolongation in COVID-19 patients in this study.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a retrospective, hospital-based, observational study. All patients with normal baseline QTc interval who were hospitalized with the diagnosis of COVID-19 infection at two hospitals in Ohio, USA were included in this study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixty-nine patients had QTc prolongation, and 210 patients continued to have normal QTc during hospitalization. The baseline QTc intervals were comparable in the two groups. Patients with QTc prolongation were older (mean age 67 vs. 60, P 0.003), more likely to have underlying cardiovascular disease (48% versus 26%, P 0.001), ischemic heart disease (29% versus 17%, P 0.026), congestive heart failure with preserved ejection fraction (16% versus 8%, P 0.042), chronic kidney disease (23% versus 10%, P 0.005), and end-stage renal disease (12% versus 1%, P\u2009&lt;\u20090.001). Patients with QTc prolongation were more likely to have received hydroxychloroquine (75% versus 59%, P 0.018), azithromycin (18% vs. 14%, P 0.034), a combination of hydroxychloroquine and azithromycin (29% vs 7%, P\u2009&lt;\u20090.001), more than 1 QT prolonging agents (59% vs. 32%, P\u2009&lt;\u20090.001). Patients who were on angiotensin-converting enzyme inhibitors (ACEi) were less likely to develop QTc prolongation (11% versus 26%, P 0.014). QTc prolongation was not associated with increased ventricular arrhythmias or mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Older age, ESRD, underlying cardiovascular disease, potential virus mediated cardiac injury, and drugs like hydroxychloroquine\/azithromycin, contribute to QTc prolongation in COVID-19 patients. The role of ACEi in preventing QTc prolongation in COVID-19 patients needs to be studied further.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-021-01963-1","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T06:02:28Z","timestamp":1617084148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Coronavirus disease 2019 (COVID-19) and QTc prolongation"],"prefix":"10.1186","volume":"21","author":[{"given":"Khalid","family":"Changal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Paternite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Mack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spiro","family":"Veria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rehana","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitra","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronak","family":"Soni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanveer","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mujeeb","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Kasi","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"1963_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25678","author":"H Lu","year":"2020","unstructured":"Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.25678.","journal-title":"J Med Virol"},{"key":"1963_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","volume":"91","author":"DS Hui","year":"2020","unstructured":"Hui DS, Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health: the latest 2019 novel coronavirus outbreak in Wuhan. China Int J Infect Dis. 2020;91:264\u20136. https:\/\/doi.org\/10.1016\/j.ijid.2020.01.009.","journal-title":"China. Int J Infect Dis."},{"key":"1963_CR3","unstructured":"Wuhan Municipal Health Commission. Report of novel coronavirus-infected pneumonia in China. Published January 20, 2020. Accessed 31 Jan 2020. http:\/\/wjw.wuhan.gov.cn\/front\/web\/showDetail\/2020012009077."},{"key":"1963_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.0757","author":"CI Paules","year":"2020","unstructured":"Paules CI, Marston HD, Fauci AS. Coronavirus infections\u2014more than just the common cold. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.0757.","journal-title":"JAMA"},{"key":"1963_CR5","unstructured":"Wuhan Municipal Health Commission. Report of clustering pneumonia of unknown etiology in Wuhan City. Published December 31, 2019. http:\/\/wjw.wuhan.gov.cn\/front\/web\/showDetail\/2019123108989."},{"key":"1963_CR6","unstructured":"Center for disease control. Accessed on 27 Dec 2020. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/cases-updates\/cases-in-us.html#1."},{"issue":"11","key":"1963_CR7","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061\u20139.","journal-title":"JAMA"},{"key":"1963_CR8","doi-asserted-by":"crossref","unstructured":"Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, Jain SS, Burkhoff D, Kumaraiah D, Rabbani L, Schwartz A. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020.","DOI":"10.1161\/CIRCULATIONAHA.120.046941"},{"issue":"9","key":"1963_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41569-020-0413-9","volume":"17","author":"M Nishiga","year":"2020","unstructured":"Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543\u201358. https:\/\/doi.org\/10.1038\/s41569-020-0413-9.","journal-title":"Nat Rev Cardiol"},{"key":"1963_CR10","doi-asserted-by":"publisher","first-page":"100557","DOI":"10.1016\/j.ijcha.2020.100557","volume":"29","author":"F Kwenandar","year":"2020","unstructured":"Kwenandar F, Japar KV, Damay V, Hariyanto TI, Tanaka M, Lugito N, Kurniawan A. Coronavirus disease 2019 and cardiovascular system: a narrative review. IJC Heart Vasc. 2020;29:100557.","journal-title":"IJC Heart Vasc"},{"key":"1963_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1540-8167.2006.00408.x","volume":"17","author":"I Goldenberg","year":"2006","unstructured":"Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is \u201cnormal.\u201d J Cardiovasc Electrophysiol. 2006;17:333\u20136.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1963_CR12","doi-asserted-by":"publisher","unstructured":"Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, van Herpen G, Wagner GS, Wellens H; American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society. AHA\/ACCF\/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009;53(11):982\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2008.12.014.","DOI":"10.1016\/j.jacc.2008.12.014"},{"key":"1963_CR13","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.10.145144","author":"K Rosenke","year":"2020","unstructured":"Rosenke K, Jarvis MA, Feldmann F, et al. Hydroxychloroquine proves ineffective in hamsters and macaques infected with SARS-CoV-2. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.06.10.145144.","journal-title":"bioRxiv"},{"key":"1963_CR14","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"56","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56:105949\u2013105949.","journal-title":"Int J Antimicrob Agents"},{"key":"1963_CR15","doi-asserted-by":"publisher","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","volume":"34","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier J-C, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020;34:101663\u2013101663.","journal-title":"Travel Med Infect Dis"},{"key":"1963_CR16","doi-asserted-by":"publisher","unstructured":"RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, Landray MJ. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030\u201340. https:\/\/doi.org\/10.1056\/NEJMoa2022926.","DOI":"10.1056\/NEJMoa2022926"},{"issue":"20","key":"1963_CR17","doi-asserted-by":"publisher","first-page":"33819","DOI":"10.1016\/j.ijcard.2020.09.038","volume":"S0167\u20135273","author":"A Bernardini","year":"2020","unstructured":"Bernardini A, Ciconte G, Negro G, Rondine R, Mecarocci V, Viva T, Santini F, de Innocentiis C, Giannelli L, Witkowska E, Locati ET, Castelvecchio S, Marrocco-Trischitta MM, Vicedomini G, Menicanti L, Pappone C. Assessing QT interval in COVID-19 patients: safety of hydroxychloroquine-azithromycin combination regimen. Int J Cardiol. 2020;S0167\u20135273(20):33819\u201325. https:\/\/doi.org\/10.1016\/j.ijcard.2020.09.038.","journal-title":"Int J Cardiol"},{"issue":"6","key":"1963_CR18","doi-asserted-by":"publisher","first-page":"e008662","DOI":"10.1161\/CIRCEP.120.008662","volume":"13","author":"M Saleh","year":"2020","unstructured":"Saleh M, Gabriels J, Chang D, Soo Kim B, Mansoor A, Mahmood E, Makker P, Ismail H, Goldner B, Willner J, Beldner S, Mitra R, John R, Chinitz J, Skipitaris N, Mountantonakis S, Epstein LM. Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT interval in patients With SARS-CoV-2 infection. Circ Arrhythm Electrophysiol. 2020;13(6):e008662. https:\/\/doi.org\/10.1161\/CIRCEP.120.008662.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"9","key":"1963_CR19","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.hrthm.2020.05.014","volume":"17","author":"E Chorin","year":"2020","unstructured":"Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, Knotts R, Bar-Cohen R, Kogan E, Barbhaiya C, Aizer A, Holmes D, Bernstein S, Spinelli M, Park DS, Stefano C, Chinitz LA, Jankelson L. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine\/azithromycin. Heart Rhythm. 2020;17(9):1425\u201333. https:\/\/doi.org\/10.1016\/j.hrthm.2020.05.014.","journal-title":"Heart Rhythm"},{"key":"1963_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2020.07.016","author":"TF O\u2019Connell","year":"2020","unstructured":"O\u2019Connell TF, Bradley CJ, Abbas AE, Williamson BD, Rusia A, Tawney AM, Gaines R, Schott J, Dmitrienko A, Haines DE. Hydroxychloroquine\/azithromycin therapy and QT prolongation in hospitalized patients with COVID-19. JACC Clin Electrophysiol. 2020. https:\/\/doi.org\/10.1016\/j.jacep.2020.07.016.","journal-title":"JACC Clin Electrophysiol"},{"issue":"5","key":"1963_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/00045391-199909000-00005","volume":"6","author":"V Ranade","year":"1999","unstructured":"Ranade V, Molnar J, Khokher T, Agarwal A, Mosnaim A, Somberg JC. Effect of angiotensin-converting enzyme therapy on QT interval dispersion. Am J Ther. 1999;6(5):257\u201361. https:\/\/doi.org\/10.1097\/00045391-199909000-00005.","journal-title":"Am J Ther"},{"issue":"4","key":"1963_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1742-7843.2012.00901.x","volume":"111","author":"J Klimas","year":"2012","unstructured":"Klimas J, Vaja V, Vercinska M, Kyselovic J, Krenek P. Discrepant regulation of QT (QTc) interval duration by calcium channel blockade and angiotensin converting enzyme inhibition in experimental hypertension. Basic Clin Pharmacol Toxicol. 2012;111(4):279\u201388. https:\/\/doi.org\/10.1111\/j.1742-7843.2012.00901.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"20","key":"1963_CR23","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605\u201310.","journal-title":"Circulation"},{"issue":"2","key":"1963_CR24","doi-asserted-by":"publisher","first-page":"F398","DOI":"10.1152\/ajprenal.90488.2008","volume":"296","author":"MJ Soler","year":"2009","unstructured":"Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2009;296(2):F398\u2013405.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1963_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.yjmcc.2016.05.012","volume":"97","author":"X Wang","year":"2016","unstructured":"Wang X, Ye Y, Gong H, et al. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1\u20137)-Mas axes in pressure overload-induced cardiac remodeling in male mice. J Mol Cell Cardiol. 2016;97:180\u201390.","journal-title":"J Mol Cell Cardiol"},{"key":"1963_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12872-020-01658-z","volume":"20","author":"C Sardu","year":"2020","unstructured":"Sardu C, Marfella R, Maggi P, et al. Implications of AB0 blood group in hypertensive patients with covid-19. BMC Cardiovasc Disord. 2020;20:373. https:\/\/doi.org\/10.1186\/s12872-020-01658-z.","journal-title":"BMC Cardiovasc Disord"},{"issue":"17","key":"1963_CR27","doi-asserted-by":"publisher","first-page":"e016948","DOI":"10.1161\/JAHA.120.016948","volume":"9","author":"C Sardu","year":"2020","unstructured":"Sardu C, Maggi P, Messina V, Iuliano P, Sardu A, Iovinella V, Paolisso G, Marfella R. Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of Southern Italy. J Am Heart Assoc. 2020;9(17):e016948. https:\/\/doi.org\/10.1161\/JAHA.120.016948.","journal-title":"J Am Heart Assoc"},{"key":"1963_CR28","doi-asserted-by":"publisher","unstructured":"Browning DJ. Pharmacology of chloroquine and hydroxychloroquine. hydroxychloroquine and chloroquine retinopathy. 2014:35\u201363. https:\/\/doi.org\/10.1007\/978-1-4939-0597-3_2.","DOI":"10.1007\/978-1-4939-0597-3_2"},{"issue":"6","key":"1963_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41591-020-0888-2","volume":"26","author":"E Chorin","year":"2020","unstructured":"Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C, Aizer A, Holmes D, Bernstein S, Spinelli M, Park DS, Chinitz LA, Jankelson L. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med. 2020;26(6):808\u20139. https:\/\/doi.org\/10.1038\/s41591-020-0888-2.","journal-title":"Nat Med"},{"issue":"7","key":"1963_CR30","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2337\/dc20-0723","volume":"43","author":"C Sardu","year":"2020","unstructured":"Sardu C, D\u2019Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, Maggi P, Coppola N, Paolisso G, Marfella R. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care. 2020;43(7):1408\u201315. https:\/\/doi.org\/10.2337\/dc20-0723.","journal-title":"Diabetes Care"},{"issue":"1","key":"1963_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12933-020-01047-y","volume":"19","author":"C Sardu","year":"2020","unstructured":"Sardu C, Gargiulo G, Esposito G, Paolisso G, Marfella R. Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19. Cardiovasc Diabetol. 2020;19(1):76. https:\/\/doi.org\/10.1186\/s12933-020-01047-y.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"1963_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.diabet.2020.05.005","volume":"46","author":"R Marfella","year":"2020","unstructured":"Marfella R, Paolisso P, Sardu C, Bergamaschi L, D\u2019Angelo EC, Barbieri M, Rizzo MR, Messina V, Maggi P, Coppola N, Pizzi C, Biffi M, Viale P, Gali\u00e9 N, Paolisso G. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. Diabetes Metab. 2020;46(5):403\u20135. https:\/\/doi.org\/10.1016\/j.diabet.2020.05.005.","journal-title":"Diabetes Metab"},{"issue":"11","key":"1963_CR33","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s00125-020-05216-2","volume":"63","author":"C Sardu","year":"2020","unstructured":"Sardu C, D\u2019Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, Maggi P, Coppola N, Paolisso G, Marfella R. Hyperglycaemia on admission to hospital and COVID-19. Diabetologia. 2020;63(11):2486\u20137. https:\/\/doi.org\/10.1007\/s00125-020-05216-2.","journal-title":"Diabetologia"},{"issue":"5","key":"1963_CR34","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1172\/JCI79273","volume":"125","author":"G Santulli","year":"2015","unstructured":"Santulli G, Pagano G, Sardu C, Xie W, Reiken S, D\u2019Ascia SL, Cannone M, Marziliano N, Trimarco B, Guise TA, Lacampagne A, Marks AR. Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J Clin Invest. 2015;125(5):1968\u201378. https:\/\/doi.org\/10.1172\/JCI79273.","journal-title":"J Clin Invest"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-01963-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-021-01963-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-01963-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T06:03:01Z","timestamp":1617084181000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-01963-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1963"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-01963-1","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"assertion":[{"value":"18 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IRB approval was obtained from Promedica Health system in Toledo, OH, USA. The study protocol was carried out in accordance with the Declaration of Helsinki. Obtained from IRB Promedica Health system in Toledo, OH, USA. Was waived by the IRB Promedica Health system in Toledo, OH, USA due to retrospective design of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}